|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Characteristic | | Loi | Buffa | Wang |  |
|  |  |  |  | Training set | Validation set |
| Sample size | | 263 | 134 | 80 | 129 |
| Age, years  Median (SD) | | 64 (10) | 57 (10) | 54 (13) | \* |
| Histologic | |  |  |  | \* |
| Grade | 1 | 50 | 30 | 37 |  |
|  | 2 | 130 | 64 | 12 |  |
|  | 3 | 43 | 27 | 2 |  |
|  | unknown | 40 | 13 | 29 |  |
| Tumor stage | |  |  |  | \* |
|  | T1 | 108 | 55 | 38 |  |
|  | T2 | 136 | 70 | 41 |  |
|  | T3  unknown | 6  13 | 9 | 1 |  |
| Lymph node status | | |  |  |  |
|  | negative | 114 | 78 | 80 | 129 |
|  | positive | 140 | 56 |  |  |
|  | unknown | 9 |  |  |  |
| Adjuvant tamoxifen | | Yes | Yes | No | No |
| Median Follow-up | | |  |  |  |
| (years) |  | 7 | 10 | 7 | 7 |

Table S5: Clinicopathological parameters

\* The validation group did not differ from the total group in any of the characteristics of patients or tumors (Wang et al 2005; Lancet)